One of the most dreaded feelings for an investor is when the stock they just bought is overvalued, or they missed out on an undervalued opportunity by not acting fast enough.

But what if you had the insights to effectively evaluate a company like Neuropace Inc before investing? Investing requires a certain perspective to avoid being overly confident in a company or worried about cyclical changes. A smart way to take the guesswork out of knowing when to buy or sell Neuropace Inc’s stock is to have the right tools and resources as well as a clear monitoring process.

In this article, we go over a few key elements for understanding Neuropace Inc’s stock price such as:

• Current stock price and volume
• Stock price history
• Upgrades and downgrades from analysts
• Stock price momentum as measured by its relative strength

About Neuropace Inc (NPCE)

Before we jump into Neuropace Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

NeuroPace, Inc. is a commercial-stage medical device company. The Company is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company?s differentiated RNS System is a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company is developing its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. RNS System is a device that records brain activity data and allows clinicians to monitor patients. RNS System monitors the brain?s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company?s RNS System is engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.

Want to learn more about Neuropace Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Neuropace Inc. The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.

Neuropace Inc’s Stock Price as of Market Close

As of September 15, 2023, 4:00 PM CST, Neuropace Inc’s stock price was $8.66.

Neuropace Inc is up 8.11% from its previous closing price of $8.01.

During the last market session, Neuropace Inc’s stock traded between $7.93 and $9.35. Currently, there are 25.47 million shares of Neuropace Inc stock available for purchase.

Unfortunately, Neuropace Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Neuropace Inc Stock Price History

Neuropace Inc’s (NPCE) price is currently down 7.77% so far this month.

During the month of September, Neuropace Inc’s stock price has reached a high of $9.50 and a low of $7.11.

Over the last year, Neuropace Inc has hit prices as high as $9.50 and as low as $1.22. Year to date, Neuropace Inc’s stock is down 14.09%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Neuropace Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 14, 2023, there was 1 analyst who downgraded Neuropace Inc’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Neuropace Inc’s financial health and valuation. It is possible for a stock to appear cheap based on one valuation metric but appear expensive on another. It is also possible for one valuation ratio to be associated with outperforming stocks during certain periods of time but not others.

Therefore, AAII developed a composite valuation to help resolve such issues. AAII’s Value Grade analyzes six distinct variables: price-to-sales (P/S) ratio, price-earnings (P/E) ratio, the ratio of enterprise value to earnings before interest, taxes, depreciation and amortization (EV/EBITDA), shareholder yield, price-to-book-value (P/B) ratio and price-to-free-cash-flow (P/FCF) ratio.

Neuropace Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Neuropace Inc (NPCE) by visiting AAII Stock Evaluator.

Relative Price Strength of Neuropace Inc

Relative price strength addresses the relationship between a stock price’s trend and the price trend of the market. This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. The weighted four-quarter relative price strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40%, and each of the three previous quarters are given a weighting of 20%.

As of September 14, 2023, Neuropace Inc has a weighted four-quarter relative price strength of 44.63%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Neuropace Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Neuropace Inc Stock Price: Bottom Line

As of September 15, 2023, Neuropace Inc’s stock price is $8.66, which is up 8.11% from its previous closing price.

At AAII, we stress that investors should never buy or sell a stock solely based on its stock price. Past returns do not guarantee future performance. Therefore, you should consider multiple ratios, fundamentals and analytics before making a decision. Whether you decide it’s a good time to buy or sell Neuropace Inc’s stock based on its stock price forecast is ultimately up to you.

It’s important to understand that stock prices are driven by a variety of factors, but ultimately the price at any given moment is due to the supply and demand in the market. Stock price overviews, like the one you just read, only give you a small snapshot of a company’s performance, value and momentum.

By becoming an A+ Investor subscriber, you will have full access to analytics, grades, stock screens, commentary and more so you can invest with confidence.